Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. DPZ
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

TD Cowen on Intellia Therapeutics (NTLA): 'We see the Ph. III results as solid'

April 27, 2026 10:48 AM EDT

TD Cowen analyst Joseph Thome reiterated a Buy rating on Intellia Therapeutics (NASDAQ: NTLA).

The analyst comments "NTLA released Ph. III data of its in vivo gene editing candidate lonvo-z for the treatment of HAE this morning. The trial hit both primary and... More